Anti-phospho-FoxO1 (pS218) antibody
Recognises FoxO1 transcriptional regulator phosphorylated at serine 218 in Western blots and immunohistochemistry with a strong signal and low background noise
Angiosarcoma tissue sample immunostaining. Biopsie from patients suffering from angiosarcoma.
FoxO1 phosphorylation status correlates in angiosarcoma patient survival (Riddell et al 2018 Nat Commun). The survival time of the pSer218 FoxO1 negative group was significantly longer than that of the pSer218 FoxO1 positive groups.
Formaldehyde-fixed paraffin block patient tissue samples were cut into 5-7 μM sections then deparaffinized in xylene and rehydrated in a graded ethanol series. This was followed by antigen retrieval in sodium citrate buffer by boiling the slides for 15 min. The tissue was then blocked in 5% FCS + 0.1% Tween-20 for 30 min at room temperature followed by incubation with primary antibodies overnight at 4 degrees (anti-pSer218-FoxO 1:100; anti-VE-Cadherin 1:100; R&D Systems AF938) Tissue was then washed and secondary antibodies were applied.
Image provided courtesy of Dr. Masanori Nakayama Laboratory
|Antibody||Anti-phospho-FoxO1 (pS218) antibody|
|Antigen Peptide||KLH conjugated synthetic peptide crb1200468e|
|Protein ID||UniProtKB - Q12778|
|Cross-Reactivity||Human, rat, mouse. May also recognise the equivalent serine in FoxO3/4/6|
|Target Protein Species||Human, rat, mouse. May also recognise the equivalent serine in FoxO3/4/6|
|Validation||WB (1:500), ELISA (1:1000), IHC (1:100)|
|Target||phosphorylated FoxO1 (pS218)|
|Storage Stabilisers||The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.|
|Disease Area||Cancer, Cell signalling, Metabolism|
|Storage||The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.|
Riddell, M., Nakayama, A., Hikita, T., Mirzapourshafiyi, F., Kawamura, T., Pasha, A., Li, M., Masuzawa, M., Looso, M., Steinbacher, T., Ebnet, K., Potente, M., Hirose, T., Ohno, S., Fleming, I., Gattenlöhner, S., Aung, P., Phung, T., Yamasaki, O., Yanagi, T., Umemura, H. and Nakayama, M. (2018). aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability. Nature Comm, 9(1). PMID: 30559384
Wilhelm, K., Happel, K., Eelen, G., Schoors, S., Oellerich, M., Lim, R., Zimmermann, B., Aspalter, I., Franco, C., Boettger, T., Braun, T., Fruttiger, M., Rajewsky, K., Keller, C., Brüning, J., Gerhardt, H., Carmeliet, P. and Potente, M. (2016). FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature, 529(7585), 216-220. PMID: 26735015
Forkhead box O1 (FoxO1) is a transcriptional regulator of cell growth and proliferation controlled by a receptor tyrosine kinase signalling pathway (the vascular endothelial growth factor A (VEGF-A)/phosphatidylinositol-3-OH kinase (PI3K)/protein kinase B (PKB/Akt) pathway). FoxO1 is phosphorylated in the DNA binding domain at serine 218 by aPKCλ. FoxO1 Ser218 phosphorylation and aPKC expression correlate with poor patient prognosis in various cancers.
VEGF/PI3K/Akt signalling results in FoxO1 cytoplasmic localisation and its inactivation. Cytoplasmically localised FoxO1 is associated with cellular myelocytomatosis (c-Myc) expression and endothelial cell (EC) proliferation. Abnormal atypical protein kinase C (aPKC)/FoxO1/c-Myc signalling contributes to excessive EC proliferation in angiosarcoma and when constitutively active, FoxO1 leads to lethality due to heart defects.